Acceleron Pharma Inc (XLRN): Steven D Ertel , EVP & Chief Operating Officer of Acceleron Pharma Inc sold 32,270 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 6, 2016 to the Securities and Exchange Commission. The shares were sold at $33.93 per share for a total value of $1,115,191.75 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 6, 2016, Kevin F Mclaughlin (SVP, CFO and Treasurer) sold 25,300 shares at $34.66 per share price.On Jul 6, 2016, John L Knopf (CEO and President) sold 100,000 shares at $34.06 per share price.Also, On Apr 8, 2016, Steven D Ertel (EVP & Chief Operating Officer) sold 32,270 shares at $32.00 per share price.On Apr 8, 2016, Matthew L Sherman (EVP & Chief Medical Officer) sold 26,000 shares at $32.00 per share price.
Shares of Acceleron Pharma Inc (XLRN) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -2.505 points or -7.10% at $32.765 with 4,26,407 shares getting traded. Post opening the session at $34.95, the shares hit an intraday low of $32.54 and an intraday high of $35.3 and the price vacillated in this range throughout the day. The company has a market cap of $1,220 M and the number of outstanding shares has been calculated to be 3,72,20,760 shares. The 52-week high of Acceleron Pharma Inc is $50.86 and the 52-week low is $20.
Company has been under the radar of several Street Analysts.Acceleron Pharma Inc is Initiated by Barclays to Overweight and the brokerage firm has set the Price Target at $40. The Rating was issued on Apr 27, 2016.
Acceleron Pharma Inc. is a biopharmaceutical company focused on the discovery development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s research focuses on key natural regulators of cellular growth and repair particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. By combining its discovery and development know-how including its knowledge of the TGF-b superfamily and its internal protein engineering and manufacturing capabilities the Company has built a discovery and development platform that has generated therapeutic candidates with new mechanisms of action. The Company has four internally discovered therapeutic candidates that are in clinical trials.